Expertise in
11
conditions

Turgut Tatlisumak

UCL Queen Square Institute Of Neurology, Queen Square, 
London, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
UCL Queen Square Institute Of Neurology, Queen Square, 
London, ENG, GB 

Overview

Turgut Tatlisumak practices practicing medicine in London, United Kingdom.

Tatlisumak is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Stroke, Mesenteric Venous Thrombosis, Thrombophlebitis, Deep Vein Thrombosis, and Thrombectomy.

They are actively involved in clinical research, co-authoring 365 peer reviewed articles and participating in 4 clinical trials.

Locations

UCL Queen Square Institute Of Neurology, Queen Square, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

International Intracranial Artery Dissection Study
International Intracranial Artery Dissection Study
Enrollment Status: Recruiting
Publish Date: November 13, 2024
Intervention Type: Other
Swiss Trial of Decompressive Craniectomy Versus Best Medical Treatment of Spontaneous Supratentorial Intracerebral Hemorrhage (SWITCH): a Randomized Controlled Trial
Swiss Trial of Decompressive Craniectomy Versus Best Medical Treatment of Spontaneous Supratentorial Intracerebral Hemorrhage (SWITCH): a Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 2
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Enrollment Status: Terminated
Publish Date: December 04, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

365 Total Publications

Acute non-alcoholic caffeinated beverage consumption as a trigger for cryptogenic ischemic stroke in the young: findings from the SECRETO study.
Acute non-alcoholic caffeinated beverage consumption as a trigger for cryptogenic ischemic stroke in the young: findings from the SECRETO study.
Journal: Journal of neurology
Published: February 26, 2026

Frequently Asked Questions about Turgut Tatlisumak

Is Turgut Tatlisumak a top-rated expert for Stroke?

MediFind is an objective health platform that identifies experts based on real-world data. Turgut Tatlisumak is classified as an Elite expert for Stroke, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Turgut Tatlisumak participate in research or clinical trials?

Yes. Turgut Tatlisumak has published 365 articles and abstracts on conditions like Stroke. You can view a list of Turgut Tatlisumak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tatlisumak's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile